All News

Found 736 articles

• Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

  8/21/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online.

• Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

  8/8/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of data from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin has been published by the Journal of the American College of Cardiology (JACC): Heart Failure.

• Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/3/2023

  Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended June 30, 2023 and provided an update on key corporate milestones.

• Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

  7/28/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the markets close.

• Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

  6/24/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.

• Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

  6/20/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that clinical study results relating to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain, and INPEFA™ (sotagliflozin), its recently approved drug for heart failure, will be featured as Oral Presentations focused on treatment of complications of diabetes during the American Diabetes Association’s 83rd Scientific Sessions, June 23-26, 2023.

• UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

  6/15/2023

  Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

• Brand Institute Partners with Lexicon Pharmaceuticals on the Brand Name Development for FDA-Approved INPEFA™ (sotagliflozin)

  6/6/2023

  Brand Institute is proud to announce its work with Lexicon Pharmaceuticals, Inc. in developing the brand name INPEFA™ (sotagliflozin), which was approved by the FDA on May 26, 2023.

• Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference

  6/6/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place June 7-9, 2023.

• Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

  6/5/2023

  Lexicon Pharmaceuticals, Inc. announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock.

• Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer

  6/1/2023

  Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.

• Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

  6/1/2023

  Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001.

• Lexicon Announces Proposed Public Offering of Common Stock - May 31, 2023

  5/31/2023

  Lexicon Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.

• Gastrointestinal Drugs Market (Type, Application) Growth Sturdy at 4.9% CAGR to Outstrip $71,300.28 Million by 2027 – The Insight Partners

  5/31/2023

  According to our new research study on “Gastrointestinal Drugs Market to 2027 – Global Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel,” the Gastrointestinal Drugs Market Size was valued at US$ 49,043.38 million in 2019 and is projected to reach US$ 71,300.28 million by 2027;

• 

  Lexicon Breaks Sotagliflozin Losing Streak with FDA Nod in Heart Failure

  5/30/2023

  Following a series of stumbles in Type 1 diabetes, Lexicon’s dual SGLT inhibitor sotagliflozin finally won the FDA's approval in heart failure and will be marketed as Inpefa.

• Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

  5/26/2023

  Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with.

• 

  FDA Action Alert: Blueprint, Indivior and Lexicon

  5/22/2023

  Blueprint Medicines, Indivior PLC and Lexicon Pharmaceuticals are all awaiting FDA decisions this week.

• Gastrointestinal Drugs Market Value Worth $71.30 Billion, Globally, by 2027 at 4.9% CAGR | The Insight Partners

  5/15/2023

  The Insight Partners published latest research report on "Gastrointestinal Drugs Market Sales Report, Size, Share, Trends, Growth and Demand Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution Channel and Geography" the global market size is projected to reach USD 71,300.28 million by 2027 from USD 49,043.38 million in 2019;

• New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

  5/10/2023

  Lexicon Pharmaceuticals, Inc., announced that results of a new investigator-initiated economic analysis, based on results from the SOLOIST-WHF Phase 3 outcomes study of its investigational medicine sotagliflozin, were presented on May 9 at the International Society for Pharmacoeconomics and Outcomes Research annual meeting in Boston, Massachusetts.

• Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

  5/2/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones.